Artivion, Inc. (NYSE:AORT) SVP Sells $442,500.00 in Stock

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Marshall S. Stanton sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $29.50, for a total transaction of $442,500.00. Following the completion of the transaction, the senior vice president now owns 64,200 shares of the company's stock, valued at approximately $1,893,900. The trade was a 18.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Stock Performance

AORT traded up $0.08 on Wednesday, reaching $29.85. The company had a trading volume of 131,037 shares, compared to its average volume of 440,139. The stock has a 50-day moving average price of $26.83 and a 200-day moving average price of $27.46. The company has a quick ratio of 3.95, a current ratio of 5.53 and a debt-to-equity ratio of 1.08. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $32.33. The stock has a market capitalization of $1.27 billion, a PE ratio of -59.70 and a beta of 1.62.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. The company had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. As a group, research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on AORT shares. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Canaccord Genuity Group assumed coverage on Artivion in a report on Tuesday. They issued a "buy" rating and a $35.00 price objective for the company. JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $32.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Next Century Growth Investors LLC grew its holdings in Artivion by 107.6% in the first quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock valued at $25,140,000 after purchasing an additional 530,122 shares during the period. Peregrine Capital Management LLC purchased a new position in Artivion in the first quarter valued at about $7,650,000. Wasatch Advisors LP lifted its position in shares of Artivion by 27.7% during the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after purchasing an additional 226,160 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Artivion in the fourth quarter valued at about $5,573,000. Finally, First Trust Advisors LP acquired a new stake in Artivion during the fourth quarter valued at approximately $4,771,000. Hedge funds and other institutional investors own 86.37% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.